Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 13, Issue 1, 2003, Pages 53-63

  Witcher, Jennifer W ^a   Long, Amanda ^a   Smith, Brian ^a   Sauer, John Michael ^a   Heilgenstein, John ^a   Wilens, Timothy ^b   Spencer, Thomas ^b   Biederman, Joseph ^b  

^a ELI LILLY AND COMPANY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ATOMOXETINE; CYTOCHROME P450 2D6; NORTAMOXIFEN; UNCLASSIFIED DRUG;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; OPEN STUDY; SCHOOL CHILD;

EID: 0038556715     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454603321666199     Document Type: Article

References (17)

1. American Psychiatric Association: Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994, pp 78-85.
2. Evans W, Relling M, Petros W, Meyer W, Mirror J, Crom W: Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 45:568-573, 1989.
3. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L: Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 25: 296-301, 1985.
4. Gehlert DR, Gackenheimer SL, Robertson DW: Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 157:203-206, 1993.
5. Hechtman L: Assessment and diagnosis of attentiondeficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:481-498, 2000.
6. Jacqz-Aigrain E, Cresteil T: Cytochrome P450-dependent metabolism of dextromethorphan: Fetal and adult studies. Dev Pharmacol Ther 18: 161-168, 1992.
7. Kearns GL: Pharmacogenetics and development: Are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 7:220-233, 1995.
8. Ladona M, Lindstrom B, Thyr C, Peng D, Rane A: Differential fetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 323:295-302, 1991.
9. Leeder JS, Gotschall RR, Gaedigk A, Adcock K, Wilson JT, Kearns GL: Acquisition of function CYP2D6 and CYP3A4 activities in vivo in the first year of life. Drug Metab Rev 32(Suppl 2):281, 2000.
10. Michelson D, Adler L, Spencer T, Reimherr F, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120, 2003.
11. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, and the Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108(5):E83, 2001.
12. Relling M, Cherrie J, Schell M, Petros W, Meyer W, Evans W: Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 50:308-313, 1991.
13. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA: Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30: 319-323, 2003.
14. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA: Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. 31:98-107, 2003.
15. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea JG, Witcher J, Zerwas S: An open-label, dose-ranging study of tomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11(3):251-265, 2001.
16. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695, 1998.
17. Wong DT, Threlkeld PG, Best KL, Bymaster FP: A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222: 61-65, 1982.